IABCR Journal Header

Article Viewer

Search

Article QR Code

ORIGINAL ARTICLE

10.21276/iabcr.2017.3.2.16
Comparative Evaluation of Cost – Effectiveness and Medication Adherence Between Olanzapine and Iloperidone in Patients of Psychosis
Download PDF     Print

April-June 2017 | Vol 3 | Issue 2 | Page :72-77

Shivangna Singh1*,Pankaj Kumar2,Abhinav Kuchhal 3,Amit Kumar4,Alka Yadav1 ,Imran Zaheerr1 ,Vivek Gautam5

1Assistant Professor, 2Assistant Professor, Dept. of Pharmacology, 3Senior Resident, Dept. of Psychiatry, Rohilkhand Medical College & Hospital, Barelly (UP), 4MSc Demonstrator Dept. of Pharmacology, FH Medical College & Hospital, Tundla (UP), 5Dept. of Medicine, SN Medical College & Hospital, Agra (UP).

How to cite this article: Singh S, Kumar P, Kuchhal A, Kumar A, Yadav A, Zaheer I, Gautam V. Comparative Evaluation of Cost – Effectiveness and Medication Adherence Between Olanzapine and Iloperidone in Patients of Psychosis. Int Arch BioMed Clin Res. 2017;3(2):72-77.DOI:10.21276/iabcr.2017.3.2.16

ABSTRACT

Background: To assess the cost – effectiveness between Iloperidone and Olanzapine in relation to different measures of effectiveness and to evaluate significance of medication adherence and costs and outcomes. Methods: A prospective, randomized, comparative, flexible dose clinical study of 1 year duration was conducted in 100 first episode (drug naïve) cases of psychosis attending to psychiatric outdoor patient department of Rohilkhand Medical College and Hospital, Bareilly. 50 patients each in olanzapine (OLZ) and Iloperidone (ILO) group comprised the sample size. Patients were regularly evaluated by senior psychiatrist for dose titration. OLZ 10-20mg/day and ILO 6-12mg/day were used. Least expensive brands available in our hospital pharmacy were used. Cost – effectiveness and medication adherence were measured as per the formula. Results: It was observed that ILO (8mg/day) controlled 65-75% cases and 12mg/day dose controlled > 90% cases of psychosis. Whereas OLZ showed this level of control respectively with 10 – 15mg/day (average 12.5mg/day) and 15-20mg/day (average 17.5mg/d). Since olanzapine in 15-20mg/day dose cause more metabolic adverse events particularly obesity, hyperglycemia and dyslipidemia which need further management hence overall olanzapine is not cost-effective. 42(87.5%) cases had medication possession ratio (MPR) >90% in ILO group compared to 18 (37.5%) cases in OLZ group. Increased medication adherence led to better control and outcomes. Patients with <90% MPR had developed more adverse events and were mostly living in rural areas. Conclusions: Iloperidone is comparatively more cost-effective than olanzapine to control > 90% of patients on long term use.

Keywords: Cost-effectiveness, Medication possession ratio, Atypical antipsychotics

REFERENCES
  1. WHO, ICD-10 classification of mental and behavioral disorders; AITBS Publishers, 10th edition, 2007, pp 86-109.
  2. Jonathan M. Pharmacology of psychosis and mania, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Ed. Brunton LL, Chabner BA, Knollman BC, MC Graw Hill publication, 12th Ed. 2011, pp 417-57.
  3. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J MCP 2003; 9: 544-50.
  4. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. circulation 2009; 119: 3028-35.
  5. Kyanko KA, Franklin RH, Angell SY. Adherence to chronic disease medications among New Youk City Medicaid participants. J Urban Health 2013; 90: 323-28.
  6. Sokol MC, Mc Guigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and health care cost. Medical Care 2005; 43: 521-30.
  7. Kumar P, Kapoor AK, Singh HK, Kulshrestha M. Comparative evaluation of cost effectiveness between ramipril versus telmisartan in cases of hypertension associated with type 2 diabetes mellitus. IJCP 2016; 26:719-36.
  8. Paltra S, Sehgal VK, Gupta AK et al. Comparative study to evaluate efficacy and cost-effectiveness of olmesartan versus telmisartan, in patients of stage-1 hypertension. IJMDS 2015; 4(1): 568-76.
  9. Li YC, Huang WL. Effects of adherence to statin therapy on health care outcomes and utilizations in Taiwan: A population based study. Bio Med Res Intern. 2015; Article ID 149573, 8 pages.
  10. Sadock B, Sadock V. Schizophrenia. Kaplan and Sadock’s Synopsis of Psychiatry, Ed. Sadock BJ, Sadock VA, Lippincott Williams & Wilkins Publication, 10th edition, 2007, pp 467-97.
  11. Leucht S, Wahlbeck K, Hamann J et al. New generation antipsychotics versus low potency conventional antipsychotics: A systemic review and metaanalysis. Lancet 2003; 361(369): 1581-89.
  12. Balt SL, Galloway GP, Baggott MJ et al. Mechanisms and genetics of antipsychotic associated weight gain. Clin. Pharmacol Ther 2011; 90(1): 179-83.
  13. Mc Kenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals (results from the STELLAR trial). Curr. Med Res Opin 2003; 19(8): 689-98.
  14. Brown WV, Bays HE, Hassman DR et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52 week trial. Am Heart J 2002; 144(6): 1036-43.
  15. Prosser LA, Stinnett AA, Goldman PA et al. Cost-effectiveness of cholesterol – lowering therapies according to selected patients characteristics. Am Intern Med 2000; 132(10): 769-79.
  16. Grover SA, Coupal L, Paquet S et al. Cost-effectiveness of 3-hydroxy 3-methylglutaryl – co enzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159(6): 593-600.
  17. Singh S, Kapoor AK, Singh HK et al. A long-term comparative evaluation of metabolic profile and tolerability of olanzapine versus iloperidone in drug naïve patients of psychosis. Delhi Psychia J 2016; 19:66-77.
  18. World Health Organization, Adherence to long term therapies: Evidence for Action, World Health Organization, Geneva, Switzerland 2003.
  19. Schlenk EA, Burke LE, Rand C. Behavioral strategies to improve medication – taking compliance, in Compliance in Health Care and Research, LE Burke and IS Ockene Eds., pp 57-70, Futura Publishing, Arnonk, N.Y., USA. 2001.
  20. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health System Pharmacy 2009; 66: 358-65.
  21. Lage MJ, Hassan MK. The relationship between antipsychotics medication adherence and patient outcomes among individuals diagnosed with bipolar disorder a retrospective study. Ann Gen Psychia 2009, 8: 9pages.
  22. Tang CH, Hsieh MH, Hung ST et al. One year post hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population based study. Bipolar Disorders 2010; 12: 859-65.
  23. Andrade SE, Kahler KH, Frech F et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiology, Drug Safety 2006; 15: 565-74.
  24. Vlasnik JJ, Aliotta SL, De Lor B. Medication Adherence: factors influencing compliance with prescribed medication plans. Care Manager 2005; 16: 47-51.
  25. Wouters H, Dijk LV, Geers HCJ. Understanding statin non-adherence: knowing which perceptions and experiences matter to different patients. PLOS ONE, journal pone. 0146272 pages 12

Published by Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.
Publication Manager: Dr. Tayyaba Farhan
Index Copernicus